KRAS and non-small cell lung carcinoma: However, a breakthrough was achieved in the treatment landscape when the US Food and Drug Administration (FDA) approved direct KRAS G12C inhibitor Sotorasib for advanced or metastatic NSCLC adult patients having KRAS G12C local mutation, with patients receiving one prior systemic therapy.